Macfarlanes has advised Atlas Health Capital, a specialist private equity firm established to invest in European healthcare companies, on the successful raise of its debut fund, Atlas Health Fund I, which was oversubscribed closing at its £400m hard cap.
Established in 2025, Atlas Health Capital will focus on buyout opportunities across selected European healthcare markets, including the UK and Ireland, DACH, Benelux and the Nordics. The firm targets specialist healthcare subsectors in MedTech, Niche Pharma and Animal Health. The fundraise was launched in February and initial close held within two months.
The Macfarlanes team was led by Private Funds Partner Harriet Miller with Head of Sponsor Solutions Stephen Pike, with support from Senior Counsel Sweta Tandle and Associate Romy Ronan.
Atlas was advised by fundraising advisor firm, First Point Equity, and fund administration and appointed representative services provided by Langham Hall.
Harriet Miller said: "We are pleased to have supported Atlas on the successful close of its debut fund at the hard cap. The fund reflects continued interest in European healthcare as an important vertical for investment, and it is encouraging to see emerging managers with specialist expertise attracting strong backing from a global investor base."